Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426
Authors
Powles, T.Plimack, E. R.
Stus, V.
Waddell, Thomas
Gafanov, R.
Pouliot, F.
Nosov, D.
Melichar, B.
Soulieres, D.
Borchiellini, D.
Vynnychenko, I.
McDermott, R. S.
Azevedo, S. J.
Tamada, S.
Kryzhanivska, A.
Li, C.
Burgents, J. E.
Molife, L. R.
Rini, B. I.
Bedke, J.
Affiliation
Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, and Queen Mary University of London, LondonIssue Date
2022
Metadata
Show full item recordCitation
Powles T, Plimack ER, Stus V, Waddell T, Gafanov R, Pouliot F, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301334.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.4513Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.4513Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.4513